Adjuvant Chemotherapy for Colorectal Cancer: State of the Art and Future Perspectives
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (1 May 2022) | Viewed by 3540
Special Issue Editors
2. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
Interests: liquid biopsy; colorectal cancer; CDX2 marker; translational research
Interests: liquid biopsy; colorectal cancer; CDX2 marker; lung cancer; translational research
Special Issue Information
Dear Colleagues,
Colorectal cancer (CRC) is a major health issue worldwide. A considerable challenge is the identification of patients at high risk of recurrence after curative intent surgery. Currently, staging is based upon the pathological analysis of the resected specimen, and it is the gold standard for determining prognosis and for adjuvant chemotherapy (ACT) decision making. However, despite an optimal initial treatment, up to 40% of patients will relapse. The identification of new predictive and prognostic markers could help to identify patients at high risk of relapse and establish innovative therapeutic options to optimize adjuvant treatment. Plasma circulating tumor DNA is a potential new biomarker detecting minimal residual disease (MRD) and accurately monitoring patients’ response to ACT. Additionally, the characterization of circulating tumor cells may determine whether any novel approach to MRD can lead to the selection of personalized treatments that improve response over current standard therapies. On the other hand, the value of CDX2 expression, deep-learning radiomics-based prediction of distant metastasis, and generation of organoids as a preclinical model may help to better select patients to ACT and develop new strategies guiding CRC patient treatment.
Dr. Noelia Tarazona
Dr. Francisco Gimeno-Valiente
Dr. Elena Duréndez Sáez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- localized colon cancer
- pathological staging
- adjuvant chemotherapy
- circulating tumor DNA
- CDX2 expression
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
